| Symbol | MNPR |
|---|---|
| Name | MONOPAR THERAPEUTICS |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 1000 SKOKIE BLVD SUITE 350, WILMETTE, IL 60091 |
| Telephone | 8473880349 |
| Fax | — |
| — | |
| Website | https://www.monopartx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001645469 |
| Description | Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The companys pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers. Additional info from NASDAQ: |
Vu Quan Anh 🟡 adjusted position in 507 shares (1 derivative) of Monopar Therapeutics (MNPR) at $92.59 Transaction Date: Jun 30, 2026 | Filing ID: 022631
Read moreDirector Robinson Chandler 🟡 adjusted position in 4.1K shares (1 derivative) of Monopar Therapeutics (MNPR) at $92.59 Transaction Date: Jun 30, 2026 | Filing ID: 022630
Read moreCittadine Andrew 🟡 adjusted position in 2.3K shares (1 derivative) of Monopar Therapeutics (MNPR) at $92.59 Transaction Date: Jun 30, 2026 | Filing ID: 022628
Read moreMonopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
Read more(90% Positive) MONOPAR THERAPEUTICS (MNPR) Announces Clinical Development Update
Read moreMonopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
Read moreMonopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
Read moreMonopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
Read moreMonopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06980506 | MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor … | — | Cancer | Available | — | — | ClinicalTrials.gov |
| NCT06980519 | MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor… | — | Cancer | Available | — | — | ClinicalTrials.gov |
| NCT06617169 | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors | Phase1 | Solid Tumor, Adult | Recruiting | 2024-10-08 | 2027-01-01 | ClinicalTrials.gov |
| NCT06337084 | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid … | Phase1 | Solid Tumor, Adult | Recruiting | 2024-05-30 | 2026-04-01 | ClinicalTrials.gov |
| NCT05043649 | Camsirubicin + Pegfilgrastim to Determine MTD in ASTS | Phase1 | Advanced Soft-tissue Sarcoma | Terminated | 2021-09-22 | 2024-05-13 | ClinicalTrials.gov |
| NCT04648020 | Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral … | Phase2 | Chemoradiotherapy-Induced Severe Oral Mucositis | Terminated | 2021-02-11 | 2023-05-14 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo Mucoadhesive Buccal Tablet | Other | Phase PHASE2 | Chemoradiotherapy-Induced Severe Oral Mucositis | TERMINATED | NCT04648020 |
| Clonidine HCl Mucoadhesive Buccal Tablet | Other | Phase PHASE2 | Chemoradiotherapy-Induced Severe Oral Mucositis | TERMINATED | NCT04648020 |
| Camsirubicin | Other | Phase PHASE1 | Advanced Soft-tissue Sarcoma | TERMINATED | NCT05043649 |
| MNPR-101-PCTA-177Lu | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06617169 |
| MNPR-101-PCTA-177Lu | Other | Preclinical | Cancer | AVAILABLE | NCT06980519 |
| MNPR-101-DFO*-89Zr | Other | Preclinical | Cancer | AVAILABLE | NCT06980506 |
| PET/CT Diagnostic Imaging | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06337084 |
| MNPR-101-DFO*-89Zr | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06337084 |
| MNPR-101-PCTA-177Lu | BIOLOGICAL | Preclinical | Cancer | AVAILABLE | NCT06980519 |
| MNPR-101-DFO*-89Zr | DRUG | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06337084 |
| Camsirubicin | DRUG | Phase PHASE1 | Advanced Soft-tissue Sarcoma | TERMINATED | NCT05043649 |
| Placebo Mucoadhesive Buccal Tablet | DRUG | Phase PHASE2 | Chemoradiotherapy-Induced Severe Oral Mucositis | TERMINATED | NCT04648020 |
| Clonidine HCl Mucoadhesive Buccal Tablet | DRUG | Phase PHASE2 | Chemoradiotherapy-Induced Severe Oral Mucositis | TERMINATED | NCT04648020 |